Comparison Study of a New Combination of 2 Marketed Medications (Esomeprazole and Naprosyn) Versus Naprosyn Alone
Launched by ASTRAZENECA · Oct 8, 2009
Trial Information
Current as of April 28, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects must have a body weight greater than 50 kg and BMI within the range 18-30(inclusive).
- • Subjects must be in good health, as assessed during pre-study medical examination and by review of screening results
- • Subjects must understand the procedures involved and agree to participate in the study by giving fully informed, written consent
- Exclusion Criteria:
- • Significant intercurrent disease of any type, in particular liver, kidney, cardiovascular disease, any form of diabetes or significant gastrointestinal disorder which could affect drug absorption, or any history of gastric or duodenal ulceration.
- • Ingestion of any naproxen, omeprazole, esomeprazole or related drugs prior to the recruitment interview, such that these drugs will have been ingested in the 4 weeks prior to the day set for the first Period 1 dose
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brisbane, Queensland, Australia
Patients applied
Trial Officials
Terry Hurst
Study Director
Q-Pharm Phase one unit
Jo Marjason
Principal Investigator
Q-Pharm Phase one unit
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials